Dasatinib Drugs Market Expected To Reach $2.07 Billion By 2030 As Growth Accelerates At 6.3% CAGR
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Dasatinib Drugs Market Growth From $1.62 Billion In 2026 To $2.07 Billion By 2030 At A CAGR Of 6.3%
The dasatinib drugs market has experienced robust expansion over recent years, with its value projected to rise from $1.53 billion in 2025 to $1.63 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.3%. This historical growth was driven by factors such as the approval of tyrosine kinase inhibitors for leukemia treatment, a growing incidence of chronic myeloid leukemia, the clinical effectiveness of dasatinib in resistant cases, the broadening reach of oncology treatment facilities, and the increased availability of oral targeted therapies.
The dasatinib market is anticipated to experience notable expansion over the coming years, projected to reach $2.08 billion by 2030, advancing at a compound annual growth rate (CAGR) of 6.3%. This forecasted growth is driven by factors such as the increasing number of leukemia patients, a growing preference for personalized cancer treatments, wider availability of generic oncology medications, the rise of home-based cancer care services, and continuous progress in targeted drug innovation. Key trends shaping the market during this period include a greater focus on targeted cancer therapies, a higher adoption rates of oral oncology drugs, a surge in demand for generic dasatinib variants, the growing use of combination therapy regimens, and enhanced patient compliance facilitated by convenient oral drug forms.
Download A Free Sample Report For Comprehensive Market Insights:
Dasatinib Drugs Market Growth Drivers: What Factors Are Accelerating Expansion?
The anticipated growth of the dasatinib drug market in the coming period is being fueled by an increasing prevalence of chronic myeloid leukemia (CML). Chronic myeloid leukemia, a malignancy of the bone marrow and blood, is characterized by the uncontrolled proliferation of abnormal white blood cells. Environmental exposures and lifestyle-related risk factors are key contributors to this rising CML incidence. Disease management is supported by the dasatinib drug market through inhibition of the BCR-ABL tyrosine kinase protein, which is responsible for the unchecked multiplication of leukemic cells. For example, data from the American Cancer Society (ACS), a US-based cancer organization, indicated that CML cases in the United States climbed to 8,930 in 2023 from 8,860 in 2022. Hence, the expanding prevalence of chronic myeloid leukemia (CML) is driving the dasatinib drug market forward.
Dasatinib Drugs Market Segment Performance And Strategic Opportunities
The dasatinib drugs market covered in this report is segmented –
1) By Product Type: Tablets, Oral Suspension, Other Products
2) By Indication: Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Other Indications
3) By End User: Hospitals, Specialty Clinics, Home Healthcare
Subsegments:
1) By Tablets: 20 mg Tablets, 50 mg Tablets, 70 mg Tablets, 80 mg Tablets
2) By Oral Suspension: 20 mg Or 5 mL Oral Suspension, 40 mg Or 5 mL Oral Suspension
3) By Other Products: Combination Therapies, Generic Dasatinib Products
Dasatinib Drugs Market Trends: What Is Shaping Future Industry Growth?
Major pharmaceutical players in the dasatinib drugs market are prioritizing the development of generic versions to broaden their market presence, provide more affordable treatment options, and enhance access for patients undergoing long-term cancer therapy. Generic dasatinib medications are therapeutically equivalent to the branded product, containing the same active ingredient, dosage strength, quality, and clinical effectiveness at a reduced price, which boosts affordability, fosters market competition, and eases the economic strain on both patients and healthcare systems. For example, in September 2024, Apotex Corp., a pharmaceutical firm based in Canada, introduced the first generic version of Sprycel (dasatinib) in the United States for managing specific types of leukemia in adults and children, delivering a high-quality, lower-cost option that improves treatment accessibility and encourages competitive pricing dynamics in the dasatinib drugs market.
Dasatinib Drugs Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the dasatinib drugs market are Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Sun Pharmaceutical Industries Limited, Hetero Drugs Limited, Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Limited, Intas Pharmaceuticals Ltd., Cipla Limited, Lupin Limited, MSN Laboratories Pvt. Ltd., Hikma Pharmaceuticals plc, Zhejiang Hisun Pharmaceutical Co. Ltd., Biocon Limited, Alkem Laboratories Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Mylan N.V., Manus Aktteva Biopharma LLP
Access The Complete Dasatinib Drugs Market Report:
Dasatinib Drugs Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the dasatinib drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dasatinib drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
